Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Expert Review of Clinical Pharmacology|July 18, 2017
Atezolizumab for the treatment of non-small cell lung cancerFernando C Santini, Charles M RudinCancer Journal (Sudbury, Mass.)|January 24, 2018
PD-1/PD-L1 Axis in Lung CancerFernando C Santini, Matthew D HellmannLung Cancer (Amsterdam, Netherlands)|October 1, 2019
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)Ana C Z Gelatti, Alexander Drilon, Fernando C SantiniLung Cancer (Amsterdam, Netherlands)|September 26, 2021
NTRK fusions in lung cancer: From biology to therapyGuilherme Harada, Fernando C Santini, Clare Wilhelm, et al.Endocrine-Related Cancer|October 14, 2017
Endocrine side effects of cancer immunotherapyPriscilla Cukier, Fernando C Santini, Mariana Scaranti, et al.Clinical Imaging|February 10, 2022
Radiogenomics in personalized management of lung cancer patients: Where are we?Jose Arimateia Batista Araujo-Filho, Maria Mayoral, Natally Horvat, et al.JTO Clinical and Research Reports|July 3, 2026
Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung CancerDaniel Reinhorn, Jonathan Kuten, Isabel Preeshagul, et al.Oncotargets and Therapy|April 25, 2017
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancersJoshua K Sabari, Fernando C Santini, Alison M Schram, et al.Lung Cancer (Amsterdam, Netherlands)|July 24, 2018
Clinical outcomes of patients with resected, early-stage ALK-positive lung cancerJamie E Chaft, Ibiayi Dagogo-Jack, Fernando C Santini, et al.JCO Precision Oncology|June 29, 2023
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung CancerRohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg, et al.Pageof 2